Finzony

Madrigal Pharmaceuticals, Inc.

MDGL Healthcare
₹ 518.76
12.30%

Live Market Data

Market Cap₹ 1,190 Cr.
Current Price₹ 518.76
High / Low₹615 / 265
Stock P/E0.0
Book Value₹26.4
Dividend Yield0.00 %
ROCE-0.2 %
ROE-0.4 %

About Company

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Industry Segment

Biotechnology

Price Chart

Loading Chart...

Technical Analysis

Technical Outlook

Short TermBullish
Mid TermBullish
Long TermNeutral
Resistance₹496.98
Support₹314.02

Valuation Check

Fair Value Assessment
Overvalued

Research Reports

Daily – Vickers Top Buyers & Sellers for 01/27/2026

Daily – Vickers Top Buyers & Sellers for 01/21/2026

Quarterly Results

ParticularsDec 25Sept 25Jun 25Mar 25Dec 24
Total Revenue (Cr)32.1128.7321.2813.7210.33
Net Income (Cr)-5.86-11.42-4.23-7.32-5.94
EPS (₹)-2.57-5.08-1.9-3.32-2.71

Annual Profit & Loss

Particulars20252024202320221970
Total Revenue (Cr)95.8418.01000
Operating Exp (Cr)120.2467.1838.0529.360
Net Income (Cr)-28.83-46.59-37.36-29.540
EPS (₹)-12.85-21.9-19.99-17.230

Balance Sheet

ParticularsDec 25Sept 25Jun 25Mar 25Dec 24
Total Assets (Cr)125.96136.25101.5499.66104.22
Total Liabilities (Cr)65.6973.6731.9428.628.79
Total Equity (Cr)60.2762.5769.671.0675.44

Key Ratios Fundamentals

Valuation

P/E Ratio (TTM)
-
Forward P/E
40.55
PEG Ratio
-
Price / Book
19.66
EV / EBITDA
-33.36

Profitability

ROE
-42.49%
ROA
-16.30%
Profit Margin
-30.08%
Operating Margin
-18.57%

Liquidity & Debt

Current Ratio
4.01
Quick Ratio
3.60
Debt / Equity
57.68
Total Cash (Cr)
98.36

Price Statistics

Beta
-0.96
52W High
615.00
52W Low
265.00
Dividend Yield
-

Pattern Unavailable

Detailed shareholding breakdown is not currently provided by the exchange.